CRSP Stock-Based Compensation
Crispr Therapeutics Ag · Stock-Based Compensation
CRSP Stock-Based Compensation
Latest reported$17.32Mperiod ending
CRSP Quarterly Stock-Based Comp ($1.35M → $17.32M)
Quarterly stock-based compensation
High-resolution chart · PNG
CRSP stock-based compensation history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 17,316,000 | |
| 16,324,000 | |
| 18,076,000 | |
| 16,604,000 | |
| 17,607,000 | |
| 20,212,000 | |
| 21,947,000 | |
| 21,543,000 | |
| 23,672,000 | |
| 19,405,000 | |
| 18,420,000 | |
| 19,968,000 | |
| 21,765,000 | |
| 20,875,000 | |
| 22,805,000 | |
| 24,545,000 | |
| 24,852,000 | |
| 25,745,000 | |
| 25,768,000 | |
| 26,199,000 | |
| 28,331,000 | |
| 22,092,000 | |
| 18,930,000 | |
| 17,240,000 | |
| 15,697,000 | |
| 14,151,000 | |
| 11,857,000 | |
| 11,343,000 | |
| 11,186,000 | |
| 9,671,000 | |
| 13,025,000 | |
| 8,054,000 | |
| 8,324,000 | |
| 5,582,000 | |
| 6,979,000 | |
| 4,868,000 | |
| 3,280,000 | |
| 3,746,000 | |
| 4,028,000 | |
| 2,293,000 | |
| 3,501,000 | |
| 1,022,000 | |
| 1,176,000 | |
| 1,029,000 | |
| 131,000 | |
| 1,348,000 |